Alphatec Holdings Inc. stocks have been trading up by 7.07 percent after upbeat coverage highlighted strong growth prospects and momentum
Click Here for a Millionaire's POV on Trading ATEC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Alphatec Holdings (ATEC) plans to report first quarter 2026 results on 2026/05/05, with a webcast and Q&A that could shift sentiment once numbers are out.
- Management will present at the Bank of America 2026 Healthcare Conference, which may boost visibility and trigger fresh institutional interest in the name.
- The company granted about 59,000 RSUs to 43 new non-executive hires, signaling ongoing staff expansion but adding modest share-based dilution.
- Recent price action shows a bounce from the mid-$9 area back above $10, suggesting dip buyers are active into the upcoming earnings date.
Weekly Update Apr 27 – May 01, 2026: On Sunday, May 03, 2026 Alphatec Holdings Inc. stock [NASDAQ: ATEC] is trending up by 7.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – neutral
Alphatec (ATEC) occupies a focused, high-growth niche in spine surgery with revenue compounding near 30–40% over three to five years and Q4 2025 sales of ~$213 million, but profitability remains weak. Gross margin is a strong 69.6%, yet EBIT margin is -12.8% and pretax margin -32.2%, with ROA at roughly -18–22%. Leverage is elevated: long‑term debt of ~$525 million versus just $12 million of equity and a long‑term debt‑to‑capital ratio near 1.0. Liquidity is adequate (current ratio 2.1), but equity dilution and stock‑based comp drive inflated price‑to‑book and fragile capital structure.
Technically, ATEC shows a constructive short‑term uptrend, with closes stepping from 9.30 to 10.45 over the past several sessions and a clean series of higher lows (9.30 → 9.35 → 9.75 → 10.36). The 10.00 area is emerging as a key pivot where prior resistance should now act as support. Intraday five‑minute candles recently showed consistent dip‑buying above that zone with expanding volume on pushes through 10.30–10.40. A tactical long setup is a pullback buy near 10.00–10.10 with a tight stop below 9.70.
More Breaking News
- ATEC Stock Sets Up Ahead Of Q1 2026 Earnings Catalyst
- Summit Therapeutics Stock Plunges 27% In Sharp Selloff
- ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan
- RIVN Stock Slides As Rivian Tightens Funding And Faces Storm Risks
Near‑term catalysts center on the May 5, 2026 Q1 print and management’s visibility at the Bank of America Healthcare Conference, which should highlight sustained revenue momentum and adoption of ATEC’s spine platforms but also ongoing losses and leverage. Versus broader Healthcare and MedTech benchmarks, ATEC offers superior top‑line growth but materially worse returns and balance‑sheet risk. I view risk‑reward as skewed, favoring only aggressive growth investors: trading stance is Neutral with near‑term support at 10.00 and resistance around 11.50–12.00.
Quick Financial Overview
Alphatec Holdings Inc. has been grinding higher in the short term, with weekly data showing a move from roughly $9.30–$9.80 back to about $10.45. Intraday, the stock traded between $9.85 and $10.50 and closed near the high of that range, which is classic strength into a known catalyst. For traders, that tells you there is appetite to own ATEC ahead of the 2026/05/05 earnings release and related webcast.
On the fundamental side, Alphatec generated about $764.2M in revenue, with strong gross margins near 69.6%. That high gross margin shows solid pricing and product positioning, but the company is still unprofitable, with EBIT margin around -12.8% and profit margin near -18.8%. Operating income in the latest quarterly data was about -$29.5M, and net income was roughly -$21.7M, so the path to consistent earnings remains a key focus.
Cash flow is more constructive than the income line might suggest. Operating cash flow of about $20.7M and free cash flow of roughly $5.7M, along with cash of around $160.8M, give Alphatec some room to keep funding growth. Leverage is meaningful, with total debt to equity near 48% and long-term debt around $525.3M, so rates and refinancing risk matter. Participation in the Bank of America 2026 Healthcare Conference and the new RSU grants both point to a company still leaning into expansion, which traders need to weigh against the negative returns on assets and capital.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.